SCHEMBL4028639

SCHEMBL4028639

O=C(O)NC1CCCc2c1[nH]c1ccc(Br)cc21

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.67
KCNH2 Q12809 1/20 0.61
BRD3 Q15059 6/20 0.60
MAPT P10636 3/20 0.60
ALOX15 P16050 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
MAPK1 P28482 1/20 0.60
DHODH Q02127 2/20 0.54
SIRT1 Q96EB6 3/20 0.52
GAA P10253 1/20 0.51
CASP6 P55212 1/20 0.51
MEN1 O00255 1/20 0.50
GLA P06280 1/20 0.50
KMT2A Q03164 1/20 0.50
CDC42 P60953 1/20 0.49
RECQL P46063 1/20 0.48
SIRT2 Q8IXJ6 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21957624 0.90 CYP2D6 (0.55) CYP2D6KCNH2BRD3MAPTALOX15
SCHEMBL4169472 0.89 MAPT (0.75) CYP2D6KCNH2BRD3MAPTALOX15
SCHEMBL4152213 0.89 BRD3 (0.75) CYP2D6KCNH2BRD3MAPTALOX15
SCHEMBL13925731 0.88 BRD3 (0.62) CYP2D6KCNH2BRD3MAPTALOX15
SCHEMBL4021888 0.88 CYP2D6 (0.67) CYP2D6KCNH2BRD3MAPTALOX15
SCHEMBL4024141 0.88 CYP2D6 (0.67) CYP2D6KCNH2BRD3MAPTALOX15
SCHEMBL4025938 0.88 CYP2D6 (0.67) CYP2D6KCNH2BRD3MAPTALOX15
SCHEMBL4172365 0.87 CYP2D6 (0.60) CYP2D6KCNH2BRD3MAPTALOX15
SCHEMBL4163639 0.86 BRD3 (0.60) CYP2D6KCNH2BRD3MAPTALOX15
SCHEMBL4025034 0.86 CYP2D6 (0.71) CYP2D6KCNH2BRD3MAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1646610-B1 TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE SMITHKLINE BEECHAM CORP (US) 2009-07-22 EP claimed
EP-1658068-B1 NOVEL CYCLOALKYL[B] CONDENSED INDOLES SMITHKLINE BEECHAM CORP (US) 2009-02-18 EP claimed
JP-2007500750-A 2007-01-18 JP claimed
EP-1646610-A1 TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE SmithKline Beecham Corporation (US) 2006-04-19 EP claimed
WO-2005005386-A1 TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE SMITHKLINE BEECHAM CORPORATION (US) 2005-01-20 WO claimed
US-20200155507-A1 THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2020-05-21 US disclosed
WO-2019005841-A1 THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200155507-A1 THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION ABCB11, SLC10A1, SLC47A1 CYP2D6 1059/4885KCNH2 1640/4885BRD3 3540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.